母体普萘洛尔或可替代侵入性胎儿手术处理绒毛膜血管瘤
母体口服普萘洛尔后,所有病例胎儿状态显著改善,心功能恢复正常,水肿消退。作者提出该药可作为侵入性胎儿手术的潜在替代方案。
要点
- 大绒毛膜血管瘤伴高输出性心衰或水肿时,可考虑母体口服普萘洛尔。
- 治疗后需动态监测胎儿心功能、水肿及肿瘤血供变化。
- 绒毛膜血管瘤与婴儿血管瘤存在生物学相似性,是尝试普萘洛尔的理论基础。
核心结论
- 4例大绒毛膜血管瘤伴胎儿失代偿者经母体普萘洛尔治疗后,胎儿状态显著改善,心功能恢复正常,水肿消退。
- 肿瘤消退及血栓形成经组织学证实,支持普萘洛尔作为侵入性胎儿手术的潜在替代选择。
研究设计与样本
- 研究对象为患大绒毛膜血管瘤且出现胎儿失代偿表现者,表现从高动力循环到进展性水肿不等。
- 干预方案为母体口服普萘洛尔。
关键影像表现/征象
- 治疗前4例胎儿均存在大绒毛膜血管瘤,伴高动力循环至进展性水肿等失代偿征象。
- 普萘洛尔治疗后,胎儿心功能恢复正常,水肿消退,肿瘤发生退缩。
- 组织学证实肿瘤内出现血栓形成。
临床应用与阅片要点
- 对伴高输出性心衰或水肿的大绒毛膜血管瘤胎儿,可考虑母体口服普萘洛尔作为治疗选项。
- 治疗期间应重点监测胎儿心功能、水肿程度及肿瘤血供演变。
- 传统侵入性治疗如胎儿镜激光和瘤内栓塞成功率有限且胎儿死亡率高,可考虑药物替代。
局限性
- 病例数仅4例,且来自单一中心,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Chorioangiomas are associated with a significant risk of fetal demise due to high-output cardiac failure. Standard invasive treatment, including fetoscopic laser photocoagulation and intratumoral embolization, shows limited success and has high fetal mortality rates. The biological parallels between chorioangiomas and infantile hemangiomas suggest that these tumors may share common therapeutic targets. Propranolol is a proven therapy for infantile hemangiomas, therefore this established efficacy provides a strong rationale for its consideration in the management of symptomatic or rapidly growing placental chorioangiomas. We hypothesized that maternal oral propranolol administration could selectively target placental chorioangiomas while preserving overall placental function, thereby offering a potential off-label therapeutic use of the drug. We report a case series of four fetuses that presented to Leiden University Medical Center, Leiden, The Netherlands, between December 2023 and May 2025 with a large chorioangioma and signs of fetal decompensation, varying from hyperdynamic circulation to evolving hydrops, and were treated with maternal propranolol. In all four cases, the fetal condition improved significantly upon propranolol treatment, with normalization of cardiac function and resolution of hydrops, paralleled by tumor regression and thrombosis confirmed histologically. These findings support a shift in the clinical management of chorioangiomas to improve fetal outcomes while minimizing procedural risks. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- van der Meeren, Slaghekke, Zaaijer, et al. Maternal propranolol as a safe alternative to invasive fetal surgery in chorioangioma management. Ultrasound Obstet Gynecol. 2026. PMID: 42406825. doi:10.1002/uog.70272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。